" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metrics Offers Proprietary Pellet Forms for Advanced Drug Release

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Unique pellet formulations help support therapeutic effectiveness of active pharmaceutical ingredients.

Metrics Inc. now offers proprietary pellet technologies enabling controlled release of active pharmaceutical ingredients (API).

The company’s advanced drug delivery technology supports the therapeutic effectiveness of API by tailoring drug release to the specific application and desired end point.

For a patient, the potential benefits of this technology are fewer doses and fewer side effects, notably gastrointestinal symptoms such as nausea – thereby increasing patient compliance. Metrics’ ability to offer these technologies results from the company’s recent acquisition by Mayne Pharma Group Limited.

Mayne Pharma has successfully applied pellet technology to a number of proprietary pharmaceuticals with modified release profiles, including Eryc™ (delayed release erythromycin), Doryx™ (delayed release doxycycline), Kadian™ (extended release morphine), Astrix™ (delayed release low-dose aspirin) and pulsed release diltiazem. The combined sales of these proprietary drugs exceed $500 million annually.

“At the end of the day, pharmaceutical science is all about making drugs as effective and tolerable as possible so that patients can experience both better health and a better quality of life when taking necessary medications,” said Dr. Brad Gold, vice president of pharmaceutical development at Metrics. “It’s exciting to offer pellet formulation to our clients – and to the patients they seek to help.”

Advanced pellet formulations can be developed for:

•    Sustained release, delivering steady levels of API 12 to 24 hours after administration.
•    Pulsed release, delivering pulses of API 12 to 24 hours after administration.
•    Modified release, delivering API in any modification from immediate release, and
•    Delayed release, allowing API to pass through the stomach undigested so that it can be absorbed in the small intestine.

Metrics and Mayne offer two technologies for formulations:

•    The first, called extrusion granulation, granulates API with excipients, which is extruded to form a core then coated by polymers. This process allows potencies up to 90 percent.
•    The second, called spheronization, applies drug particles to a “seed” core – typically sugar – with the aid of a binder. The core is coated with a polymer. This process provides a very tight size distribution of pellets. Potencies up to 60 percent are possible.

Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.

The company’s areas of expertise include quality pharmaceutical formulation development; first-time-inman (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.

Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metrics Expands with Fast-Track Product Development Laboratory
Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract services.
Friday, February 21, 2014
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!